No description
-
2023 (v1)PublicationUploaded on: October 30, 2024
-
2019 (v1)Publication
No description
Uploaded on: October 30, 2024 -
2024 (v1)Publication
Wagenlehner and colleagues 1 demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A...
Uploaded on: October 30, 2024 -
2018 (v1)Publication
Introduction: The emergence and diffusion of multidrug-resistant Gram-negative bacteria (MDR-GNB) is an unprecedented threat, with prevalences as high as 10–50% being reported in many countries. Areas covered: In the present review, we discuss the management of infections due to MDR-GNB, focusing in particular on current strategies and novel...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Introduction Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones. Areas covered The present narrative review summarizes the...
Uploaded on: October 30, 2024 -
2022 (v1)Publication
No description
Uploaded on: October 30, 2024 -
2023 (v1)Publication
IntroductionCeftolozane is a cephalosporin similar to ceftazidime in its structure, which is marketed in combination with tazobactam, a well-known & beta;-lactamase inhibitor.Areas coveredAfter a brief introduction on the drug characteristics and efficacy, we focused on available data from randomized controlled trials and post-marketing...
Uploaded on: October 30, 2024 -
2023 (v1)Publication
Purpose of review In the present narrative review, we discuss the characteristics and differences between the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines in terms on their recommendations/suggestions for the treatment of Pseudomonas aeruginosa and...
Uploaded on: October 30, 2024 -
2019 (v1)Publication
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
IntroductionInvasive candidiasis remains a leading cause of morbidity and mortality in various categories of patients at risk.Areas coveredStructure and mechanism of action, pharmacokinetics and pharmacodynamics, clinical studies, safety, and regulatory status of micafungin are explored in the present review, focusing on pediatric patients...
Uploaded on: February 14, 2024 -
2021 (v1)Publication
Purpose of review To discuss the current literature on novel agents for the treatment of carbapenem-resistant nonfermenting Gram-negative bacteria (NF-GNB) infections. Recent findings Some novel agents have recently become available that are expected to replace classical polymyxins as the first-line options for the treatment of...
Uploaded on: February 4, 2024 -
2024 (v1)Publication
The clinical spectrum of invasive pulmonary aspergillosis (IPA) has expanded in recent decades. A large group of patients admitted to intensive care units (ICU) is indeed susceptible to the development of IPA. Although timely diagnosis and antifungal therapy of IPA in this expanding population is crucial to prevent IPA-related deaths, the...
Uploaded on: October 27, 2024 -
2024 (v1)Publication
IntroductionInfluenza affects individuals of all ages and poses a significant threat during pandemics, epidemics, and sporadic outbreaks. Neuraminidase inhibitors (NAIs) are currently the first choice in the treatment and prevention of influenza, but their use can be hindered by viral resistance.Areas coveredThis review summarizes current NAIs...
Uploaded on: October 30, 2024 -
2023 (v1)Publication
Artificial intelligence (AI) and machine learning (ML) are revolutionizing human activities in various fields, with medicine and infectious diseases being not exempt from their rapid and exponential growth. Furthermore, the field of explainable AI and ML has gained particular relevance and is attracting increasing interest. Infectious diseases...
Uploaded on: October 30, 2024 -
2023 (v1)Publication
IntroductionExcessive use of antibiotics has been frequently reported in hospitalized patients with COVID-19 worldwide, compared to the actual number of bacterial co-infections or super-infections.Areas coveredIn this perspective, we discuss the current literature on the use of antibiotics and antimicrobial stewardship interventions in...
Uploaded on: October 30, 2024 -
2017 (v1)Publication
A technical error led to incorrect rendering of the author group in this article. The correct authorship is as follows: Daniele Roberto Giacobbe1, Valerio Del Bono1, Malgorzata Mikulska1, Giulia Gustinetti1, Anna Marchese2, Federica Mina3, Alessio Signori4, Andrea Orsi5, Fulvio Rudello6, Cristiano Alicino5, Beatrice Bonalumi3, Alessandra...
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Introduction: Invasive fungal diseases (IFD) remain a leading cause of morbidity and mortality in hematology patients. Within a diagnostic-driven approach, the use of the serum (1,3)-ß-D-glucan (BDG) test represents a valid tool for the early diagnosis and treatment of IFD. Areas covered: The available literature on the use of BDG in hematology...
Uploaded on: April 14, 2023 -
2020 (v1)Publication
Purpose of review To summarize the available efficacy and safety data of novel agents for treating acute bacterial skin and skin-structure infections (ABSSSI), focusing on those active against methicillin-resistant Staphylococcus aureus (MRSA). Recent findings There are now several agents active against MRSA that are approved for the treatment...
Uploaded on: October 30, 2024